Uncategorized

[ACS Nano] Researchers developed ND-dsRNA-VHH, a biocompatible carbon-based nanomaterial platform that codelivers EGFR-specific nanobodies (VHHs) and immunostimulatory double-stranded RNA, polyinosinic–polycytidylic acid (poly(I:C)).

[Genome Biology] Investigators analyzed paired baseline and post-treatment tumor samples from 50 patients with stage II–III TNBC treated with anthracycline- and taxane-based neoadjuvant chemotherapy, integrating whole-exome sequencing, RNA sequencing, global proteomics, and phosphoproteomics.

[Journal for Immunotherapy of Cancer] Scientists defined a new mechanism of barrier-mediated immune exclusion in cancer controlled by TROP2-dependent tight junctions. This mechanism drives tumor progression but can be targeted via TROP2-directed therapy to activate antitumor immunity and enhance immunotherapy response.

[Cell Death & Disease] The authors investigated the mTORC1 inhibitor everolimus as a sensitizer to 5-fluorouracil and capecitabine in breast cancer, exploring thymidylate synthase as a predictive biomarker and targeted mechanism.

[British Journal of Pharmacology] Researchers showed that cimigenoside enhances the chemical sensitivity of TNBC by regulating the γ-secretase/RBPJ-PXR axis.

[NPJ Breast Cancer] Investigators provided a real-world analysis for PARP-inhibitor use in advanced breast cancer patients treated within the prospective German PRAEGNANT registry (NCT02338167).

[European Journal of Medicinal Chemistry] The authors integrate recent advances in casein kinase 2 (CK2) biology, summarize the evolution of CK2 inhibitor classes, and outline the opportunities and remaining barriers for translating CK2 inhibition into effective cancer therapeutics.

[Cellectar Biosciences, Inc.] Cellectar Biosciences, Inc. announced that the first patient has been enrolled in the Phase Ib trial of CLR 121125 for the potential treatment of TNBC.

[Montefiore Einstein] Ulrich Steidl, MD, PhD, Director, at Montefiore Einstein Comprehensive Cancer Center has been awared the International Society for Experimental Hematology (ISEH) 2025 McCulloch & Till Award.

[Cell Research] Researchers showed that Piezo1 is highly expressed in HSCs. Both genetic deletion and prolonged chemical activation of Piezo1 impair cultured HSC function, indicating that transient mechanical activation of Piezo1 is required for maintenance of HSCs in culture.

[Blood] Through a clustered regularly interspaced short palindromic repeats/Cas9 screen with a BCL11A–enhanced green fluorescent protein reporter, scientists identified the epigenetic reader SP140 as a suppressor of hematopoiesis.

[Nature Communications] Investigators showed that multiple stress responses converge on the RIPK3-MLKL axis to induce age-related changes in HSCs.